Mass Tort Advertising Campaign
Depo-Provera (medroxyprogesterone acetate), a long-used injectable contraceptive manufactured by Pfizer Inc., has become the subject of active plaintiff litigation linking prolonged use to intracranial meningioma — a type of brain tumor. For plaintiff firms building a docket, this is a high-injury, identifiable-exposure tort with a clear manufacturer target and a claimant population that can be reached efficiently through paid social.
Intake is currently open, and the litigation landscape is developing in a way that rewards early docket-building. Mass Tort Ad Agency is running and optimizing Facebook and Instagram acquisition campaigns for firms in this space right now — and the window to accumulate quality cases at favorable acquisition costs is open today.
The central allegation is that long-term exposure to medroxyprogesterone acetate — the synthetic progestin in Depo-Provera — promotes the growth of intracranial meningiomas, brain tumors that can require surgical resection and carry serious, life-altering consequences. Pfizer Inc. is the named manufacturer. The injury profile is severe and documentable: claimants who received the injection for an extended period and subsequently received a meningioma diagnosis, particularly those who required surgery, represent the core of the docket plaintiff firms are assembling.
For advertising purposes, this tort draws a useful parallel to the early Zantac/Ranitidine litigation cycle of 2019 — a period when proactive firms that moved quickly on paid acquisition built substantial dockets ahead of the broader market. The Depo-Provera meningioma tort shares that same characteristic: a single dominant manufacturer, a discrete and serious injury, and a claimant population that is identifiable by both product use history and medical diagnosis.
The creative strategy for Depo-Provera meningioma campaigns centers on the severity and specificity of the injury. Brain tumor diagnosis — particularly one requiring surgery — is a life-defining medical event, and claimants who experienced it after years of Depo-Provera use are highly motivated to understand whether they have a claim. Ad creative that leads with the injury (meningioma / brain tumor) and connects it plainly to Depo-Provera use drives strong self-identification among the right audience. This is not a tort where claimants are uncertain whether they were exposed — women who received the injection know it, and those who had brain surgery remember it. The creative job is recognition and call-to-action, not education from scratch.
On the intake side, qualification logic should be built to capture use duration and surgical history early in the funnel, allowing firms to tier leads in real time and allocate follow-up resources to the strongest case profiles. MTAA structures campaigns with intake partners or in-house intake teams in mind, ensuring that the volume generated is pre-qualified to the firm's defined criteria before it hits the phones. Given the parallels to the early Zantac cycle, firms that move now — before CPLs reflect broad market competition — are positioned to build dockets at a meaningful cost advantage.
Mass Tort Ad Agency runs Depo-Provera / Meningioma campaigns on the same transparent model as every tort: actual Meta ad spend at cost plus a flat 15% management fee, a one-time $1,000 setup fee per tort, and $100 per signed retainer for CloudIntake qualification. No per-case markups, no lead resale, and the firm owns its ad account, pixel, creative, and claimant data.
We build, run, and qualify Depo-Provera / Meningioma claimant-acquisition campaigns end to end. Book a call and we'll walk you through the creative, audience, and intake plan.
Book a strategy call